Supplementary Table S4. Comparison of various commercially available Pan-Tumor cfDNA NGS assays suitable for prostate cancer genomic analysis with our new cfDNA assay.

cfDNA Assay	Technology	Approval	Number of Target Genes	Availability
FoundationOne @ Liquid CDx Assay	Hybridization-based capture seq	FDA/CE-IVD	324	Centralized
Guardant 360@ CDx Assay ***(Guardant Health)***	Hybridization-based capture seq	FDA/CE-IVD	129	Centralized
TriuSight™ Oncology 500 ctDNA ***(Illumina)***	Hybridization-based capture seq	RUO	523	In-house
Oncomine™ Pan-Cancer cfDNA Assay ***(ThermoFisher)***	Amplicon-based seq	RUO	44 (SNV only)	In-house
Oncomine™ Precision AssayGx ***(ThermoFisher)***	Amplicon-based seq	RUO	45 (SNV only)	In-house
Oncomine Dx Express Test™ ***(ThermoFisher)***	Amplicon-based seq	CE-IVD	42 (SNV only)	In-house
Prostate Cancer-specific cfDNA Assay ***(this study)***	Amplicon-based seq	RUO	46 (SNV+AR CNV)	In-house **(this study*)**